Researchers analyzed blood samples for 175 people older than 80. Ninety-nine participants received their second Pfizer shot three weeks after their first, while 73 got their second shot 12 weeks after their first. Fifteen participants (10 in the three-week group and five in the 12-week group) who had prior COVID-19 infections were excluded from the analysis, as prior infection can play a major part in the immune response generated after vaccination.
The study found participants who received their second dose 12 weeks after their first produced a peak antibody response 3.5 times higher than participants who received their second dose 3 weeks after the first.
“This research is crucial, particularly in older people, as immune responses to vaccination deteriorate with age,” Helen Parry, MD, the study’s lead author, said in a news release. “Understanding how to optimise COVID-19 vaccine schedules and maximise immune responses within this age group is vitally important.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
